Hunan Jiudian Pharmaceutical Co., Ltd.

SZSE:300705 Stock Report

Market Cap: CN¥5.6b

Hunan Jiudian Pharmaceutical Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Hunan Jiudian Pharmaceutical.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth17.9%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Analysis Article • Mar 19

Here's Why We Think Hunan Jiudian Pharmaceutical (SZSE:300705) Is Well Worth Watching

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Analysis Article • Mar 01

Are Investors Undervaluing Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) By 45%?

Key Insights Hunan Jiudian Pharmaceutical's estimated fair value is CN¥32.07 based on 2 Stage Free Cash Flow to Equity...
Analysis Article • Dec 31

Investors Don't See Light At End Of Hunan Jiudian Pharmaceutical Co., Ltd.'s (SZSE:300705) Tunnel And Push Stock Down 29%

Hunan Jiudian Pharmaceutical Co., Ltd. ( SZSE:300705 ) shareholders that were waiting for something to happen have been...
Analysis Article • Nov 29

We Think Hunan Jiudian Pharmaceutical (SZSE:300705) Can Stay On Top Of Its Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Analysis Article • Oct 22

Do Hunan Jiudian Pharmaceutical's (SZSE:300705) Earnings Warrant Your Attention?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Analysis Article • Aug 12

With Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) It Looks Like You'll Get What You Pay For

With a median price-to-earnings (or "P/E") ratio of close to 28x in China, you could be forgiven for feeling...
Analysis Article • Jun 23

Here's Why Hunan Jiudian Pharmaceutical (SZSE:300705) Can Manage Its Debt Responsibly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • May 21

Hunan Jiudian Pharmaceutical (SZSE:300705) Is Increasing Its Dividend To CN¥0.321

Hunan Jiudian Pharmaceutical Co., Ltd. ( SZSE:300705 ) has announced that it will be increasing its dividend from last...
Analysis Article • Apr 12

Here's Why We Think Hunan Jiudian Pharmaceutical (SZSE:300705) Might Deserve Your Attention Today

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Analysis Article • Mar 04

Earnings Not Telling The Story For Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) After Shares Rise 27%

Hunan Jiudian Pharmaceutical Co., Ltd. ( SZSE:300705 ) shares have had a really impressive month, gaining 27% after a...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hunan Jiudian Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SZSE:300705 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/20263,010404-65578N/A
12/31/20253,111473-6647N/A
9/30/20253,053469125600N/A
6/30/20253,076520202604N/A
3/31/20253,036512278655N/A
12/31/20242,931512348746N/A
9/30/20242,945508235646N/A
6/30/20242,841455286652N/A
3/31/20242,782417192571N/A
12/31/20232,6933684431N/A
9/30/20232,62037160490N/A
6/30/20232,513338-86427N/A
3/31/20232,379291-162369N/A
1/1/20232,326270-144269N/A
9/30/20222,097243-55262N/A
6/30/20221,927221-16163N/A
3/31/20221,79921457176N/A
1/1/20221,62820465191N/A
9/30/20211,45119641149N/A
6/30/20211,31716248166N/A
3/31/20211,09612263148N/A
12/31/20209788272150N/A
9/30/20209217283183N/A
6/30/20208915931144N/A
3/31/202090652-15127N/A
12/31/201992455N/A91N/A
9/30/201990065N/A64N/A
6/30/201986773N/A62N/A
3/31/201981170N/A76N/A
12/31/201880172N/A68N/A
9/30/201874667N/A40N/A
6/30/201868072N/A65N/A
3/31/201861371N/A56N/A
12/31/201753569N/A80N/A
9/30/201747272N/A86N/A
6/30/201743062N/A75N/A
3/31/201738556N/A52N/A
12/31/201637655N/A55N/A
9/30/201633439N/A35N/A
6/30/201632038N/A32N/A
3/31/201630541N/A32N/A
12/31/201529045N/A32N/A
9/30/201528143N/A30N/A
6/30/201527240N/A28N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 300705's forecast earnings growth is above the savings rate (2.4%).

Earnings vs Market: Insufficient data to determine if 300705's earnings are forecast to grow faster than the CN market

High Growth Earnings: Insufficient data to determine if 300705's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 300705's revenue is forecast to grow faster than the CN market.

High Growth Revenue: Insufficient data to determine if 300705's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 300705's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/06 17:42
End of Day Share Price 2026/06/05 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hunan Jiudian Pharmaceutical Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yizheng YangChina International Capital Corporation Limited